SRTD Biotech raises €31.5 million seed round for selective RNA therapies
Mérieux Innovation 2, NRW.Venture EU Tech&Scale and Boehringer Ingelheim Venture Fund led the financing.
SRTD Biotech has completed an oversubscribed €31.5 million seed financing to advance its preclinical RNA therapy pipeline toward applications for clinical development.
Mérieux Equity Partners led through its Mérieux Innovation 2 fund, alongside co-leads NRW.BANK’s NRW.Venture EU Tech&Scale fund and Boehringer Ingelheim Venture Fund. Eli Lilly Ventures, High-Tech Gründerfonds and Anobis Asset also participated.
The Jülich company develops RNA constructs designed to switch on inside cells carrying specific disease markers. It aims to apply the approach to cancer, autoimmune diseases and fibrosis while limiting activity in healthy tissue.
Use of funds
Advance preclinical targeted RNA therapies toward IND applications